References
- 1. Fest J, Ruiter R, Ikram MA, Voortman T, van Eijck CHJ, Stricker BH. Reference values for white blood-cell-based inflammatory markers in the Rotterdam Study: a population-based prospective cohort study. Sci Rep. 2018;8(1):10566.10.1038/s41598-018-28646-w604360930002404
- 2. Stenvinkel P. Inflammation in end-stage renal disease--a fire that burns within. Contrib Nephrol. 2005;149:185-99.10.1159/00008552515876843
- 3. Navarro JF, Milena FJ, Mora C, León C, García J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol. 2006;26(6):562–70.10.1159/00009800417167242
- 4. Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol. 2007;22(12):2011–22.10.1007/s00467-007-0524-0206494217647026
- 5. Snaedal S, Heimbürger O, Qureshi AR, et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis. 2009;53(6):1024-33.10.1053/j.ajkd.2009.02.00819394732
- 6. Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail. 2012;34(2):155–9.10.3109/0886022X.2011.64151422172001
- 7. Valente MJ, Rocha S, Coimbra S et al. Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. Mediators Inflamm. 2019;3295725.10.1155/2019/3295725660429431316299
- 8. Krzanowski M, Krzanowska K, Gajda M, et al. Pentraxin 3 as a new indicator of cardiovascular-related death in patients with advanced chronic kidney disease. Pol Arch Intern Med. 2017;127(3):170-7.10.20452/pamw.3944
- 9. Forget P, Khalifa C, Defour JP, et al. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017;10(1):12.10.1186/s13104-016-2335-5521725628057051
- 10. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.10.1093/jnci/dju12424875653
- 11. Fest J, Ruiter TR, Groot Koerkamp B, et al. The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study. Eur J Epidemiol. 2019;34(5):463-79.10.1007/s10654-018-0472-y645646930569368
- 12. Christiansen MH, Barup KØ, Samson MH. Neutrophil-lymphocyte-ratio distributions in a Danish population from general practice. Scand J Clin Lab Invest. 2019;79(1-2):75-7910.1080/00365513.2018.155585630638080
- 13. Huguet E, Maccallini G, Pardini P, et al. Reference Values for Neutrophil to Lymphocyte Ratio (NLR), a Biomarker of Cardiovascular Risk, According to Age and Sex in a Latin American Population. Curr Probl Cardiol. 2019. pii: S0146-2806(19)30054-4.
- 14. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-51.10.1161/ATVBAHA.108.179705342275422895665
- 15. Corriere T, Di Marca S, Cataudella E et al. Neutrophil-to-Lymphocyte Ratio is a strong predictor of atherosclerotic carotid plaques in older adults. Nutr Metab Cardiovasc Dis. 2018;28(1):23-7.10.1016/j.numecd.2017.10.02229241668
- 16. Verdoia M, Barbieri L, Di Giovine G et al. Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results From a Large Cohort Study. Angiology. 2016;67(1):75-82.10.1177/000331971557752925818102
- 17. Zhou S, Cai B, Zhang Y, Wang L, Liu X, Xu G. The Relationship between Neutrophil-to-Lymphocyte Ratio and Aortic Arch Calcification in Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2017;26(6):1228-32.10.1016/j.jstrokecerebrovasdis.2017.01.01228162903
- 18. Yoshitomi R, Nakayama M, Sakoh T et al. High neutrophil/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. Ren Fail. 2019;41(1):238-43.10.1080/0886022X.2019.1595645645058230942116
- 19. Yuan Q, Wang J, Peng Z et al. Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). J Transl Med. 2019;17(1):86.10.1186/s12967-019-1808-4642074630876475
- 20. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20(7):1453-64.10.1681/ASN.200807069219478096
- 21. London GM, Guerin AP, Marchais S, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731–40.10.1093/ndt/gfg41412937218
- 22. Neuen BL, Leather N, Greenwood AM, Gunnarsson R, Cho Y, Mantha ML. Neutrophil-lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients. Ren Fail. 2016;38(1):70-6.10.3109/0886022X.2015.110499026540580
- 23. Iijima K, Hashimoto H, Hashimoto M et al. Aortic arch calcification detectable on chest X-ray is a strong independent predictor of cardiovascular events beyond traditional risk factors. Atherosclerosis. 2010;210(1):137-44.10.1016/j.atherosclerosis.2009.11.01220006335
- 24. Inoue T, Ogawa T, Ishida H, Ando Y, Nitta K. Aortic arch calcification evaluated on chest X-ray is a strong independent predictor of cardiovascular events in chronic hemodialysis patients. Heart Vessels. 2012;27(2):135-42.10.1007/s00380-011-0129-121416116
- 25. Kalra SS, Shanahan CM. Vascular calcification and hypertension: cause and effect. Ann Med. 2012;44 Suppl 1:S85-92.10.3109/07853890.2012.66049822713153
- 26. Zhou S, Cai B, Zhang Y, Wang L, Liu X, Xu G. The Relationship between Neutrophil-to-Lymphocyte Ratio and Aortic Arch Calcification in Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2017;26(6):1228-32.10.1016/j.jstrokecerebrovasdis.2017.01.01228162903
- 27. Turkmen K, Ozcicek F, Ozcicek A, Akbas EM, Erdur FM, Tonbul HZ. The relationship between neutrophil-to-lymphocyte ratio and vascular calcification in end-stage renal disease patients. Hemodial Int. 2014;18(1):47-53.10.1111/hdi.1206523819627
- 28. Cai K, Luo Q, Zhu B, et al. Neutrophil-lymphocyte ratio is associated with arterial stiffness in patients with peritoneal dialysis. BMC Nephrol. 2016;17(1):191.10.1186/s12882-016-0394-4512214827881094
- 29. Guo J, Fujiyoshi A, Willcox B et al. Increased Aortic Calcification Is Associated With Arterial Stiffness Progression in Multiethnic Middle-Aged Men. Hypertension. 2017;69(1):102-8.10.1161/HYPERTENSIONAHA.116.08459514572727821619
- 30. Odink AE, Mattace-Raso FU, van der Lugt A et al. The association of arterial stiffness and arterial calcification: the Rotterdam study. J Hum Hypertens. 2008;22(3):205-7.10.1038/sj.jhh.100231518172454
- 31. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1)1–150.
- 32. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041.10.1097/HJH.000000000000194030234752
- 33. Symeonidis G, Papanas N, Giannakis I et al. Gravity of aortic arch calcification as evaluated in adult Greek patients. Int Angiol. 2002;21:233-6.
- 34. Task Force Members, Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003.10.1093/eurheartj/eht29623996286
- 35. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816.10.1093/eurheartj/ehx095
- 36. Yu HT. Progression of chronic renal failure. Arch Intern Med. 2003;163:1417–29.10.1001/archinte.163.12.1417
- 37. Jacobson HR. Chronic renal failure: pathophysiology. Lancet. 1991. 338(8764):419–23.10.1016/0140-6736(91)91042-S
- 38. Swaminathan S, Shah SV. Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int. 2011;80(5):453-63.10.1038/ki.2011.17821697810
- 39. Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8(2):56–61.10.1136/heartasia-2016-010809513339527933104
- 40. Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015;39(1-3):84-92.10.1159/00036894025662331